Published in Semin Oncol on October 01, 2010
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med (2013) 2.18
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 1.86
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials (2012) 1.72
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med (2012) 1.29
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10
Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol (2011) 1.04
Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 1.04
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One (2015) 1.01
Colitis associated with biological agents. World J Gastroenterol (2012) 1.00
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol (2012) 1.00
Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist (2012) 0.99
Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res (2014) 0.99
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother (2013) 0.94
The impact of the myeloid response to radiation therapy. Clin Dev Immunol (2013) 0.92
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs (2013) 0.88
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory. Oncoimmunology (2015) 0.88
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer (2015) 0.88
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment. J Immunol Res (2014) 0.88
Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Contemp Oncol (Pozn) (2013) 0.87
Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. Front Oncol (2013) 0.87
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis (2016) 0.84
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Med (2013) 0.84
Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol (2016) 0.84
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res (2013) 0.84
A siege of hepatitis: immune boost for viral hepatitis. Nat Med (2011) 0.84
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A (2016) 0.84
Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer (2013) 0.84
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol (2017) 0.82
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol (2015) 0.82
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.82
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 0.81
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br J Cancer (2012) 0.81
What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist (2013) 0.81
Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity. Nat Rev Urol (2012) 0.81
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res (2014) 0.81
Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia (2015) 0.79
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist (2016) 0.78
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med (2015) 0.78
Autoimmune thyroid disease elicited by NY-ESO-1 vaccination. Thyroid (2013) 0.78
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma. J Skin Cancer (2013) 0.76
Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol (2014) 0.75
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. Oncologist (2016) 0.75
The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis. Case Rep Oncol (2016) 0.75
A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer. Neuroophthalmology (2017) 0.75
Cutaneous complications of molecular targeted therapy used in oncology. J Med Life (2016) 0.75
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2013) 3.28
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res (2009) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol (2011) 1.57
Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene (2003) 1.49
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer (2012) 1.45
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res (2013) 1.43
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother (2009) 1.36
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res (2004) 1.31
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother (2013) 1.30
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol (2007) 1.30
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res (2002) 1.27
Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med (2004) 1.25
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother (2010) 1.24
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res (2007) 1.23
Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res (2008) 1.22
Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum Pathol (2009) 1.22
Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother (2003) 1.20
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother (2011) 1.19
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med (2010) 1.17
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother (2005) 1.17
Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother (2002) 1.17
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res (2012) 1.15
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol (2010) 1.11
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood (2003) 1.10
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol (2014) 1.09
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest (2014) 1.06
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02
Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol (2005) 1.00
Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep (2007) 1.00
Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med (2012) 0.99
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med (2011) 0.99
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS One (2010) 0.98
Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol (2008) 0.97
Classification and pathophysiology of skin grafts. Clin Dermatol (2005) 0.97
Anti-CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol (2010) 0.97
Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene (2003) 0.96
Biology and clinical applications of CD40 in cancer treatment. Semin Oncol (2010) 0.96
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol (2005) 0.96
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Semin Oncol (2010) 0.93
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med (2013) 0.92
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol (2010) 0.91
Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol (2003) 0.91
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol (2006) 0.90
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res (2014) 0.89
Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer (2003) 0.88
The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res (2006) 0.88
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87
Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Immunother (2012) 0.87
Heat shock proteins and their use as anticancer vaccines. Clin Cancer Res (2004) 0.87
Nucleolin protein expression in cutaneous melanocytic lesions. J Cutan Pathol (2009) 0.86
S100A13 is a new angiogenic marker in human melanoma. Mod Pathol (2010) 0.86
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells. J Cell Physiol (2002) 0.86
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res (2013) 0.84
Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma. Dermatology (2013) 0.83
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother (2015) 0.83
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother (2013) 0.82
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story. Cancer Res (2007) 0.81
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? Cancer Immunol Immunother (2014) 0.81
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother (2010) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest (2016) 0.80
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. J Cell Physiol (2011) 0.79
Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. J Cell Physiol (2004) 0.79
Epigenetic markers of prognosis in melanoma. Methods Mol Biol (2014) 0.78
Skin allograft in the treatment of toxic epidermal necrolysis (TEN). Dermatol Surg (2002) 0.78
Epigenetic immunomodulation of hematopoietic malignancies. Semin Oncol (2005) 0.78
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond. Ann N Y Acad Sci (2012) 0.77
Peptide-based vaccines for cancer therapy. Hum Vaccin Immunother (2014) 0.77
Is it the primetime for endoglin (CD105) in the clinical setting? Cardiovasc Res (2006) 0.77
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res (2015) 0.77
Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. Cancer Immunol Immunother (2009) 0.77
Epigenetics of melanoma: implications for immune-based therapies. Immunotherapy (2013) 0.76
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy? J Transl Med (2004) 0.75
About vascular patterns. Australas J Dermatol (2009) 0.75
Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours. Int J Oncol (2006) 0.75
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Cancer (2014) 0.75